

Supplementary Online Content

Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis. *Arch Dermatol*. 2011;147(4):391-398.

eTable 1. Clinical Features, Treatment, and Prognosis in 9 Japanese Anti-Mi-2 Autoantibody-Positive Patients With DM

eTable 2. Clinical Features, Treatment, and Prognosis in 25 Japanese Anti-155/140 Autoantibody-Positive Patients With DM

eTable 3. Clinical Features, Treatment, and Prognosis in 43 Japanese Anti-CADM-140 Autoantibody-Positive Patients

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Clinical Features, Treatment, and Prognosis in 9 Japanese Anti–Mi-2 Autoantibody–Positive Patients With DM

Patient No./Sex/Age, y	CK, U/L	Initial Treatment	Additional Treatment	Exacerbation	Prognosis
1/M/50	8035	mPSL pulse + PSL	mPSL pulse, IVIG, MTX	Muscle	Alive
2/M/16	10326	PSL	None	Muscle	Alive
3/M/64	7676	PSL	None	Skin, muscle	Alive
4/F66	488	PSL	None	Skin	Alive
5/F/55	604	PSL	None	Skin	Alive
6/M/38	5154	PSL	mPSL pulse	None	Alive
7/M/38	3934	PSL	None	Muscle	Alive
8/F/39	9296	PSL	mPSL pulse, CsA, Tac, CYC	None	Alive
9/M/35	2399	PSL	None	None	Alive

Abbreviations: CK, creatine kinase; CsA, cyclosporine A; CYC, cyclophosphamide; DM, dermatomyositis; IVIG, intravenous immunoglobulin; mPSL, methylprednisolone; MTX, methotrexate; PSL, prednisolone; Tac, tacrolimus.

eTable 2. Clinical Features, Treatment, and Prognosis in 25 Japanese Anti-155/140 Autoantibody-Positive Patients With DM

Patient No./Sex/ Age, y	CK, IU/L	ILD	Malignancy	Onset	Treatment for Malignancy ^a	Outcome
1/M/79	8556	-	Gastric and colon cancer	Simultaneous	Not effective	Dead
2/M/54	8670	-	Lung cancer	Simultaneous	Not effective	Dead
3/M/74	2124	-	Colon and prostate cancer	Simultaneous	Not effective	Dead
4/M/70	882	+	Lung cancer	Simultaneous	Not effective	Dead
5/M/74	594	-	Lung cancer	Simultaneous	Not effective	Dead
6/F/76	662	-	Biliary tract cancer	Malignancy→D M	Not effective	Dead
7/M/57	300	-	Pancreas cancer	DM→Malignancy	Not effective	Dead
8/M/75	1398	+	Lung cancer	Malignancy→D M	Not effective	Dead
9/M/59	480	-	Unknown	Unknown	Unknown	Alive
10/F/56	583	-	Breast cancer	Simultaneous	Effective	Alive
11/F/52	1703	+	Unknown	Unknown	Unknown	Alive
12/F/52	181	-	Unknown	Unknown	Unknown	Alive
13/F/54	60	-	Gastric cancer	Simultaneous	Not effective	Alive
14/F/46	523	-	Unknown	Unknown	Unknown	Alive
15/F/62	271	-	Ovarian cancer	Malignancy→D M	Not effective	Alive
16/F/61	235	-	Breast cancer	Malignancy→D M	Unknown	Alive
17/M/79	1214	-	Lung cancer and NHL	Malignancy→D M	Not effective	Alive
18/F/31	368	-	Unknown	Unknown	Unknown	Alive
19/F/63	581	-	Unknown	Unknown	Unknown	Alive
20/F/50	422	-	Unknown	Unknown	Unknown	Alive
21/F/74	179	-	Lung cancer	Malignancy→D M	Not effective	Alive
22/M/54	280	-	Nasopharyngeal cancer	Simultaneous	Effective	Alive
23/M/78	1940	-	Breast cancer	Simultaneous	Not effective	Alive
24/F/38	158	-	Unknown	Unknown	Unknown	Alive
25/F/72	1735	-	Lung cancer	Simultaneous	Not effective	Alive

Abbreviations: CK, creatine kinase; DM, dermatomyositis; ILD, interstitial lung disease; NHL, non-Hodgkin lymphoma.

^aEffect of treatment for malignancy on DM.

eTable 3. Clinical Features, Treatment, and Prognosis in 43 Japanese Anti-CADM-140 Autoantibody-Positive Patients

Patient, No./Sex/Age, y	Dx	ILD	RP-ILD	Pneumomedia stinum	Initial Treatment	Additional Treatment	Outcome
1/F/76	CAD M	+	+	-	PSL	None	Dead
2/F/30	DM	+	+	-	mPSL pulse + PSL	mPSL pulse, CsA, CYC	Dead
3/F/47	CAD M	+	-	+	PSL	mPSL pulse, CsA, CYC, IVIg	Dead
4/F/66	CAD M	+	+	-	PSL	Increased PSL	Dead
5/F/63	CAD M	+	+	-	PSL	mPSL pulse, CsA, CYC	Dead

6/F/63	CAD M	+	+	-	mPSL pulse + PSL	CsA	Dea d
7/F/73	CAD M	+	-	-	PSL + CsA	mPSL pulse	Dea d
8/F/57	CAD M	+	+	+	mPSL pulse + PSL	mPSL pulse, CsA, CYC	Dea d
9/F/74	DM	+	+	-	mPSL pulse + PSL	CsA	Dea d
10/F/45	CAD M	+	+	+	mPSL pulse + PSL	mPSL pulse, CsA	Dea d
11/M/49	CAD M	+	+	-	mPSL pulse + PSL	mPSL pulse, CsA, CYC	Dea d
12/F/44	CAD M	+	+	-	mPSL pulse + PSL	CsA, Tac, CYC	Dea d
13/F/59	DM	+	+	+	PSL + CsA	mPSL pulse, CsA, CYC	Dea d
14/M/51	CAD M	+	+	+	mPSL pulse + PSL	mPSL pulse	Dea d
15/F/58	CAD M	+	+	-	mPSL pulse + CsA	mPSL pulse, CsA, Tac, CYC, IVIG	Dea d
16/M/61	CAD M	+	+	+	mPSL pulse + PSL	mPSL pulse, CsA	Dea d
17/F/71	CAD M	+	+	-	mPSL pulse + PSL	mPSL pulse, CsA, CYC	Dea d
18/F/59	CAD M	+	+	-	mPSL pulse + PSL	mPSL pulse, CsA	Dea d
19/M/57	CAD M	+	+	-	PSL	mPSL pulse, increased PSL, CsA, CYC, IVIG	Dea d
20/F/53	DM	+	-	-	PSL	CYC	Aliv e
21/F/52	CAD M	+	-	+	PSL	CsA	Aliv e
22/M/22	CAD M	+	-	-	PSL	mPSL pulse, increased PSL, CsA	Aliv e
23/F/48	CAD M	+	-	-	mPSL pulse + PSL	mPSL pulse, CsA	Aliv e
24/F/57	DM	+	+	-	PSL + CsA	mPSL pulse, Tac, CYC	Aliv e
25/F/62	CAD M	+	+	-	PSL	mPSL pulse, CsA, CYC	Aliv e
26/M/34	DM	+	-	-	mPSL pulse + PSL	None	Aliv e

27/F/61	CAD M	+	-	-	mPSL pulse + Tac	mPSL pulse, CsA, CYC	Aliv e
28/F/57	CAD M	+	+	+	mPSL pulse + PSL + CsA	mPSL pulse, CsA, CYC	Aliv e
29/F/52	CAD M	+	+	-	mPSL pulse + PSL	None	Aliv e
30/F/74	CAD M	+	+	-	PSL	CsA, CYC	Aliv e
31/F/62	CAD M	+	+	-	PSL	mPSL pulse, CsA	Aliv e
32/F/44	CAD M	+	+	-	PSL	mPSL pulse, CYC	Aliv e
33/M/53	DM	+	+	-	PSL	None	Aliv e
34/M/43	DM	+	-	-	PSL	CsA	Aliv e
35/M/15	DM	+	-	-	PSL	None	Aliv e
36/F/49	CAD M	+	+	-	PSL	mPSL pulse, increased PSL, CsA, Tac, CYC, AZP	Aliv e
37/F/59	C-DM	+	+	-	mPSL pulse + PSL	CsA	Aliv e
38/F/48	C-DM	+	+	+	PSL	mPSL pulse, CYC	Aliv e
39/F/54	CAD M	+	+	-	mPSL pulse + PSL	CsA	Aliv e
40/F/66	CAD M	+	+	-	mPSL pulse + PSL	mPSL pulse, increased PSL, CsA, CYC	Aliv e
41/F/49	CAD M	-	-	-	PSL	None	Aliv e
42/F/32	DM	-	-	-	PSL	mPSL pulse	Aliv e
43/F/63	DM	-	-	-	None	None	Aliv e

Abbreviations: AZP, azathioprine; CADM, clinically amyopathic DM; CsA, cyclosporine A; CYC, cyclophosphamide; DM, dermatomyositis; Dx, diagnosis; ILD, interstitial lung disease; IVIG, intravenous immunoglobulin; mPSL, methylprednisolone; PSL, prednisolone; RP-ILD, rapidly progressive ILD; Tac, tacrolimus.